JP2005522999A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005522999A5 JP2005522999A5 JP2003564555A JP2003564555A JP2005522999A5 JP 2005522999 A5 JP2005522999 A5 JP 2005522999A5 JP 2003564555 A JP2003564555 A JP 2003564555A JP 2003564555 A JP2003564555 A JP 2003564555A JP 2005522999 A5 JP2005522999 A5 JP 2005522999A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- sequence
- polypeptide
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004196 processed proteins & peptides Human genes 0.000 claims 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims 52
- 229920001184 polypeptide Polymers 0.000 claims 51
- 150000001875 compounds Chemical class 0.000 claims 31
- 108020004707 nucleic acids Proteins 0.000 claims 23
- 102000039446 nucleic acids Human genes 0.000 claims 23
- 150000007523 nucleic acids Chemical class 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 230000004663 cell proliferation Effects 0.000 claims 17
- 230000000694 effects Effects 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 14
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 108010053754 Aldehyde reductase Proteins 0.000 claims 12
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 claims 12
- 230000002491 angiogenic effect Effects 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 230000033115 angiogenesis Effects 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000035269 cancer or benign tumor Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000003321 amplification Effects 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35360002P | 2002-01-31 | 2002-01-31 | |
| US36451702P | 2002-03-15 | 2002-03-15 | |
| US37107502P | 2002-04-09 | 2002-04-09 | |
| US37150702P | 2002-04-10 | 2002-04-10 | |
| US37298402P | 2002-04-16 | 2002-04-16 | |
| US37419402P | 2002-04-19 | 2002-04-19 | |
| US38299502P | 2002-05-24 | 2002-05-24 | |
| US38502302P | 2002-05-31 | 2002-05-31 | |
| US38885302P | 2002-06-14 | 2002-06-14 | |
| US38939502P | 2002-06-17 | 2002-06-17 | |
| US39132402P | 2002-06-25 | 2002-06-25 | |
| US39594402P | 2002-07-15 | 2002-07-15 | |
| US39772602P | 2002-07-22 | 2002-07-22 | |
| US40304602P | 2002-08-13 | 2002-08-13 | |
| US40515502P | 2002-08-22 | 2002-08-22 | |
| US40636102P | 2002-08-27 | 2002-08-27 | |
| US42119502P | 2002-10-25 | 2002-10-25 | |
| US42545602P | 2002-11-12 | 2002-11-12 | |
| US42762602P | 2002-11-19 | 2002-11-19 | |
| US43212202P | 2002-12-10 | 2002-12-10 | |
| PCT/US2003/002588 WO2003065006A2 (en) | 2002-01-31 | 2003-01-30 | Methods and compositions for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005522999A JP2005522999A (ja) | 2005-08-04 |
| JP2005522999A5 true JP2005522999A5 (enExample) | 2006-03-02 |
Family
ID=27671411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003564555A Pending JP2005522999A (ja) | 2002-01-31 | 2003-01-30 | 癌を処置するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20030157082A1 (enExample) |
| EP (1) | EP1468118A4 (enExample) |
| JP (1) | JP2005522999A (enExample) |
| AU (1) | AU2003225535A1 (enExample) |
| WO (1) | WO2003065006A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1402009A4 (en) * | 2001-05-24 | 2005-02-02 | Cephalon Inc | NEW MIXED LINEAR KINASE POLYPEPTIDE (MLK7), POLYNUCLEOTIDES ENCODING THEM, AND METHODS OF USE THEREOF |
| EP1532244A4 (en) | 2001-06-14 | 2005-12-14 | Bristol Myers Squibb Co | NEW HISTONIC HUMAN DEACETYLASES |
| US20030153018A1 (en) * | 2001-11-27 | 2003-08-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 |
| US20030199462A1 (en) * | 2002-04-23 | 2003-10-23 | Gabriel Nunez | Methods and compositions for regulating cellular signaling |
| US20040229232A1 (en) * | 2002-09-11 | 2004-11-18 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP1431399A1 (en) * | 2002-12-20 | 2004-06-23 | Clinigenetics | Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions |
| WO2005103255A1 (en) * | 2004-03-25 | 2005-11-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Formylpeptide receptor (fpr) as a target for anti-malignant glioma therapy |
| EP2256197A1 (en) * | 2004-06-14 | 2010-12-01 | Galapagos N.V. | Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases |
| EP1786925B1 (en) * | 2004-08-10 | 2010-12-08 | Oncotherapy Science, Inc. | Genes and polypeptides relating to breast cancers |
| TWI388568B (zh) | 2006-02-10 | 2013-03-11 | Genentech Inc | 抗fgf19抗體及其使用方法 |
| US8148338B2 (en) * | 2006-02-22 | 2012-04-03 | Supratek Pharma Inc. | Doxorubicin formulations for anti-cancer use |
| WO2008066498A1 (en) * | 2006-12-01 | 2008-06-05 | Agency For Science, Technology And Research | Cancer-related protein kinases |
| AU2008299779B2 (en) | 2007-08-03 | 2013-05-16 | Genentech, Inc. | Humanized anti-FGF19 antagonists and methods using same |
| US9351981B2 (en) * | 2007-09-13 | 2016-05-31 | University Of South Florida | Use of PKC-iota inhibitors for the treatment of breast cancer |
| EP2060583A1 (en) * | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| AU2016201637B2 (en) * | 2007-10-23 | 2017-05-25 | Biontech Ag | Identification of tumor-associated markers for diagnosis and therapy |
| KR20100106590A (ko) * | 2008-01-22 | 2010-10-01 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ron 항체 및 이들의 용도 |
| TWI466680B (zh) | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | Melk抗原決定位胜肽及含此胜肽的疫苗 |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| CN102803955B (zh) * | 2009-05-21 | 2015-10-21 | 系统生物学研究所 | 肝损伤的新标志物 |
| WO2010141349A1 (en) | 2009-05-30 | 2010-12-09 | University Of Toledo | Soluble guanylyl cyclase a1 and a-8r peptide as diagnostic markers of and therapeutic targets for prostate cancer |
| US9301991B2 (en) | 2009-05-30 | 2016-04-05 | The University Of Toledo | sGCalphal inhibiting compositions |
| TWI485245B (zh) | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | 經修飾之melk胜肽及含此胜肽之疫苗 |
| AU2011223710B2 (en) | 2010-03-01 | 2016-04-14 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI) |
| WO2013119825A1 (en) * | 2012-02-07 | 2013-08-15 | De Benedetti Arrigo | Modulators of tousled kinase in cellular processes |
| MX2020008581A (es) | 2018-02-21 | 2020-09-21 | Bristol Myers Squibb Co | Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| KR20020093017A (ko) * | 2000-04-03 | 2002-12-12 | 상꾜 가부시키가이샤 | 포유동물 스핑고신 키나제 유형 2 이성체, 이의 클로닝,발현 및 사용 방법 |
| MXPA02009902A (es) * | 2000-04-07 | 2003-06-17 | Arena Pharm Inc | Receptores acoplados a proteina g, conocidos, activados constitutivamente, no endogenos. |
| CA2503043A1 (en) * | 2002-10-18 | 2004-07-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
-
2003
- 2003-01-30 US US10/354,358 patent/US20030157082A1/en not_active Abandoned
- 2003-01-30 JP JP2003564555A patent/JP2005522999A/ja active Pending
- 2003-01-30 WO PCT/US2003/002588 patent/WO2003065006A2/en not_active Ceased
- 2003-01-30 EP EP03735059A patent/EP1468118A4/en not_active Withdrawn
- 2003-01-30 AU AU2003225535A patent/AU2003225535A1/en not_active Abandoned
-
2006
- 2006-11-22 US US11/603,696 patent/US20070078088A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005522999A5 (enExample) | ||
| JP2010508855A5 (enExample) | ||
| JP2004512022A5 (enExample) | ||
| JP2003501038A5 (enExample) | ||
| JP2014509853A5 (enExample) | ||
| JP2009502116A5 (enExample) | ||
| CA2362527A1 (en) | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer | |
| JP2005516605A5 (enExample) | ||
| JP2005535289A5 (enExample) | ||
| JP2005525112A5 (enExample) | ||
| JP2005512558A5 (enExample) | ||
| JP2010502192A5 (enExample) | ||
| JP2005508169A5 (enExample) | ||
| JP2005516604A5 (enExample) | ||
| JP2005508633A5 (enExample) | ||
| JP2005512528A5 (enExample) | ||
| KR101238196B1 (ko) | 대장암의 간 전이 진단용 조성물 및 그 용도 | |
| JP2016140262A (ja) | 肝細胞がんの転移性再発リスクの予測方法 | |
| JP2005513422A5 (enExample) | ||
| JP2005522228A5 (enExample) | ||
| JP2005514940A5 (enExample) | ||
| JP2005504830A5 (enExample) | ||
| JP2005514013A5 (enExample) | ||
| JP2005509416A5 (enExample) | ||
| JP2005531290A5 (enExample) |